Printer Friendly

NEW BREAST CANCER TEST

 DAYTON, Ohio, Feb. 26 /PRNewswire/ -- A Dayton, Ohio company believes it has discovered a new bio-marker for breast cancer that will allow doctors to help stop the disease before it even starts. "We think we've found a relationship between circadian rhythm of the breast and hormonal changes that indicate if a woman under fifty has breast cancer or is predisposed to it," said William Reeves, chief executive officer of Breast HealthCare Systems, Inc.
 The discovery comes at a time when the disease is the No. 1 killer of women ages 40-44 and new data questions the value of mammograms in women under 50. The new bio-marker might identify the 80 percent of breast cancer patients who develop the disease even though they had none of the classic risk factors. "We believe we've stumbled onto something pretty phenomenal," Reeves said.
 The bio-marker discovery arose from the research work of endocrinologist Dr. Keith Griffiths and pathologist Dr. Hugh Simpson.
 A handful of U.S. and European researchers now are reviewing the bio-marker data and are developing guidelines that will allow other scientists to do independent clinical studies.
 Among the few who know about the bio-marker work is Dr. John German, a diagnostic radiologist at Kettering Medical Center, who stated to the Dayton Daily News, "If the bio-marker studies hold out it has the potential for revolutionizing the way we approach, think about, diagnose and treat breast disease in women."
 Previously identified "risk factors" that seem to be related to breast cancer are all historical factors, such as having a family member with breast cancer. The bio-marker is based on a woman's own physiology.
 To test for the bio-marker, a woman wears two patented electronic sensors in her bra for a short time each evening and collects a sample of saliva each day for a full menstrual cycle.
 Neural network paradigms analyze the data collected from a hormone assays and the breast rhythms. The neural network paradigms recognize patterns indicating that a woman is likely to have breast cancer or develop it later.
 The bio-marker should help distinguish harmless growths from cancerous ones, thus making many biopsies unnecessary.
 Women with seemingly normal breasts but abnormal bio-marker variations could be at high risk for cancer and should be considered candidates for preventative drug intervention.
 -0- 2/26/93
 /CONTACT: Bill Reeves of Breast HealthCare Systems, Inc., 513-898-8418/


CO: Breast HealthCare Systems, Inc. ST: Ohio IN: HEA SU:

LC -- CL023 -- 1064 02/26/93 18:19 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 26, 1993
Words:412
Previous Article:BRITISH AMERICAN HOLDINGS LTD. ANNOUNCES COMPLETION OF PUBLIC OFFERING IN MAURITIUS OF SHARES OF BRITISH AMERICAN INSURANCE CO. (MITIUS) LTD.
Next Article:UMWA SPEAKS OUT ON YET ANOTHER 'MISLEADING' COAL INDUSTRY NEWS RELEASE
Topics:


Related Articles
Medical Zone; Jill Palmer's Family Health.
Maker of cancer test hopes to replace mammography.
FDA Approves Ventana's CB11 Antibody for Her 2/neu Diagnostic Testing.
Matritech receives patent expanding protection of company's fluid-based nuclear matrix protein cancer detection technology.
Test determines return of breast cancer.
New molecular oncology tests for metastatic and breast cancer improve patient treatment.
Clarient Launches New Breast Cancer Test.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters